216 related articles for article (PubMed ID: 32719151)
21. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
[TBL] [Abstract][Full Text] [Related]
22. Perioperative management of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society for Rheumatology.
Albrecht K; Poddubnyy D; Leipe J; Sewerin P; Iking-Konert C; Scholz R; Krüger K
Z Rheumatol; 2023 Jan; 82(Suppl 1):1-11. PubMed ID: 35235025
[TBL] [Abstract][Full Text] [Related]
23. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy.
Berardicurti O; Ruscitti P; Pavlych V; Conforti A; Giacomelli R; Cipriani P
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):593-604. PubMed ID: 32434398
[TBL] [Abstract][Full Text] [Related]
24. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
25. Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.
Goodman SM
Drugs Aging; 2015 May; 32(5):361-9. PubMed ID: 25941102
[TBL] [Abstract][Full Text] [Related]
26. Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties.
Borgas Y; Gülfe A; Kindt M; Stefánsdóttir A
BMC Musculoskelet Disord; 2020 Jun; 21(1):410. PubMed ID: 32600315
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
28. Perioperative Management of Rheumatic Disease and Therapies.
Zisa D; Goodman SM
Rheum Dis Clin North Am; 2022 May; 48(2):455-466. PubMed ID: 35400371
[TBL] [Abstract][Full Text] [Related]
29. Perioperative management of patients with rheumatoid arthritis undergoing orthopaedic surgery.
Agarwal N; Kamaraj A; McDonnell S; Khan W
J Perioper Pract; 2020 Sep; 30(9):265-270. PubMed ID: 31694466
[TBL] [Abstract][Full Text] [Related]
30. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
[TBL] [Abstract][Full Text] [Related]
31. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
32. Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift.
Chatzidionysiou K; Sfikakis PP
RMD Open; 2019; 5(2):e000993. PubMed ID: 31413870
[TBL] [Abstract][Full Text] [Related]
33. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study.
Hetland ML; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Lauridsen UB; Ellingsen T; Hansen GV; Lindegaard H; Vestergaard A; Jurik AG; Østergaard M; Hørslev-Petersen K;
Ann Rheum Dis; 2008 Jun; 67(6):815-22. PubMed ID: 17878209
[TBL] [Abstract][Full Text] [Related]
34. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Glück T; Müller-Ladner U
Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
[No Abstract] [Full Text] [Related]
35. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
36. Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.
Chandrashekara S; Shobha V; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Rheumatol Int; 2019 Mar; 39(3):497-507. PubMed ID: 30684040
[TBL] [Abstract][Full Text] [Related]
37. [Orthopedic rheumatology].
Holder M; Henniger M; Rehart S
Z Orthop Unfall; 2013 Aug; 151(4):407-21; quiz 422-3. PubMed ID: 23963988
[TBL] [Abstract][Full Text] [Related]
38. Treatment strategies are more important than drugs in the management of rheumatoid arthritis.
Drosos AA; Pelechas E; Voulgari PV
Clin Rheumatol; 2020 Apr; 39(4):1363-1368. PubMed ID: 32088801
[TBL] [Abstract][Full Text] [Related]
39. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 Among Patients With Inflammatory Rheumatic Diseases.
Esatoglu SN; Tascilar K; Babaoğlu H; Bes C; Yurttas B; Akar S; Pehlivan O; Akleylek C; Tecer D; Seyahi E; Yuce-Inel T; Alpay-Kanitez N; Bodakci E; Tekgoz E; Colak S; Bolek EC; Koca SS; Kalyoncu U; Icacan OC; Ugurlu S; Oz HE; Hamuryudan V; Hatemi G;
Front Immunol; 2021; 12():651715. PubMed ID: 33936073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
